Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis - Wikidata - wikimedia - TriplyDB

Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis

Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis

http://www.wikidata.org/entity/Q37108920

about

Sulpiride versus placebo for schizophrenia Sulpiride dose for schizophrenia Sulpiride versus other antipsychotics for schizophrenia Sulpiride versus placebo for schizophrenia Universal Health Coverage for Schizophrenia: A Global Mental Health Priority.Mental health and the global agenda: core conceptual issues.Packages of care for schizophrenia in low- and middle-income countries.Health Gains and Financial Protection Provided by the Ethiopian Mental Health Strategy: an Extended Cost-Effectiveness Analysis Closing the mental health treatment gap in South Africa: a review of costs and cost-effectiveness.Cost-effectiveness analysis of psychosocial intervention for early stage schizophrenia in China: a randomized, one-year study.Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia.International and national policy challenges in mental health.Implementing psychosocial evidence-based practices in mental health: are we moving in the right direction?Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People's Republic of China Health care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China.Service availability and utilization and treatment gap for schizophrenic disorders: a survey in 50 low- and middle-income countries Cost effectiveness of strategies to combat neuropsychiatric conditions in sub-Saharan Africa and South East Asia: mathematical modelling study.Capacity building in global mental health: professional training The relationships between patients' and caregivers' beliefs about the causes of schizophrenia and clinical outcomes in Latin American countries.An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance.Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis The state of health economic evaluation research in Nigeria: a systematic review.The state of health economic research in South Africa: a systematic review.Pharmacological treatment of schizophrenia.Pharmacological and psychosocial management of mental, neurological and substance use disorders in low- and middle-income countries: issues and current strategies.Disability studies in Sri Lanka: priorities for action.A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.Schizophrenia interventions in Vietnam: primary results from a cost-effectiveness study.Cost-effectiveness of the Mental Health and Development model for schizophrenia-spectrum and bipolar disorders in rural Kenya.The mental health workforce gap in low- and middle-income countries: a needs-based approach.Medical diplomacy and global mental health: from community and national institutions to regional centers of excellence.COllaborative Shared care to IMprove Psychosis Outcome (COSIMPO): study protocol for a randomized controlled trial.A prospective cohort study on the role of nonspecialist staff in preventing relapses and improving clinic attendance of patients with schizophrenia.Challenges for trainees in psychiatry and early career psychiatrists.Basic treatment principles for psychotic disorders in patients with epilepsy.Role of primary care in the management of schizophrenia.Combining depot antipsychotic with an assertive monitoring programme for treating first-episode schizophrenia in a resource-constrained setting.Preparation and characterization of silk fibroin hydrogel as injectable implants for sustained release of Risperidone.Systematic review of pharmacoeconomic models for schizophrenia Community-based psychosocial rehabilitation for schizophrenia service users in the north west province of South Africa: A formative study

P2860

Q24197456-3AB2A611-1027-42F8-A01C-910CFC28DAD6 Q24202897-A982753E-DC3C-4389-86D7-23C60A949EEF Q24241160-16D4A4E3-F5E6-476A-AF5E-77E1BE201AC4 Q24241525-31BDE86F-0D69-4D5A-9EF5-9542E23D5985 Q30383306-89A130DE-AC98-432A-A81F-6A4FE6F2B230 Q30395255-713DCE86-FFC9-4878-996F-9D3FC3A8A63C Q33511434-01BE5977-135D-4C80-84EB-A724F4FB7DD4 Q33589583-BC338A81-D462-447E-B6FF-E04DE0FC9673 Q33686866-D099B1CB-08DE-48AA-9746-F47D039AC7CA Q34109190-109C6D1E-9D0E-4E85-9FEB-C6582E3C14FF Q35061441-A71E4C86-EB5B-45FA-8311-A77A2E981887 Q35226884-6BA0F663-3531-4044-B942-964F5AD72FAD Q35403157-EC6D7A78-7C76-4513-A762-08E829722EE1 Q35427820-755F28AF-83E0-4135-AC41-96E45BF09F64 Q35568945-0C29CEDE-E07A-4C9C-AF01-628C6F1479EF Q35678823-94B4FA3A-2F34-43D6-AC97-22C1F31538FF Q35798043-9AAEF4A0-3550-424E-A187-7997ED68A6AD Q35908908-69913A44-8663-40A3-AEDF-3EA5AF6C914A Q35988494-FACF8C0D-FCB4-47FF-BEB8-F2153EAB3A4F Q37080239-6414FB5C-F0E2-4B9A-8D16-A58826AF3CDA Q37178416-C930FE31-6A84-41EB-B0B4-9D9C81938177 Q37765280-C94793EF-D328-4530-9B87-7FD7DDB0F3C1 Q38027235-A6F29EF5-39C3-41E5-96A5-F9DAEF2E4BDC Q38051438-426559F2-E707-43FD-B110-75E7315863C2 Q38133770-FEC0B4F4-64B7-4B48-9A21-B628EC6044E6 Q38169735-131E9E2A-39A8-4436-B54B-2EF60119F2EB Q38859087-D693155B-B0F9-42C0-8B2F-EB352AAF9C4C Q39080698-3B260823-98A5-45CF-8F17-C963A81EB2A4 Q41726287-2525D2CC-4766-4CAB-A13D-359F47AD584C Q42199267-A2AD1389-E40A-4D5A-A5A5-43FE3629782F Q42252329-B9FDF9BA-A0BB-4821-8A29-0B8C423CFF7E Q42374152-C97E9340-F990-4A87-9823-1BAA00507585 Q43235851-3EDD2562-E4EA-4F9C-9A1D-3527E49063E4 Q44958453-AE12B240-C10F-41A1-8159-2DBDB0E0D1C6 Q46681114-65C53295-B1B0-4703-A7C5-409B592CBE18 Q47140447-98077B39-E0C0-4D3C-A55A-3DC270EDEE93 Q48081253-BA70BC71-0529-4B35-A4E8-C12B20A105C2 Q49687548-CDEB5040-9434-46F7-974D-BEB4B376D387 Q57169493-83B6E347-B18A-4317-BADD-A3F927A3BB32 Q58206031-E1A89D70-6773-44A0-B2FA-F857D3DBC437

P2860

Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis

http://www.wikidata.org/entity/Q37108920

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Schizophrenia treatment in the ...... al cost-effectiveness analysis

@en

Schizophrenia treatment in the ...... l cost-effectiveness analysis.

@nl

type

label

Schizophrenia treatment in the ...... al cost-effectiveness analysis

@en

Schizophrenia treatment in the ...... l cost-effectiveness analysis.

@nl

prefLabel

Schizophrenia treatment in the ...... al cost-effectiveness analysis

@en

Schizophrenia treatment in the ...... l cost-effectiveness analysis.

@nl

P1433

Q37108920-66EC85AF-9719-4C4A-8536-C48C260C9AE9

P1476

Q37108920-E18340C1-680B-4357-A9FF-562B0ED3121F

P2093

Q37108920-132019D1-5B4C-48B4-86EB-F10D31D7AACF

Q37108920-1C3F208D-1AAC-4CD2-9657-857EABDCF307

Q37108920-6A640376-129C-4545-9FA8-7255F7D73982

Q37108920-C34FDEE1-602B-46CC-9E22-82BB57A52BC8

Q37108920-E3CAE1F4-2BDD-4357-9DF5-C07AA6A38756

Q37108920-ECBE7647-ECFC-4FA8-AAD0-43779BF48F3D

P2860

Q37108920-021E8C05-1BDC-4A66-A75F-3DC6174CF29E

Q37108920-084944FD-E0A6-488E-BCC1-39CFE2F957A7

Q37108920-0AB6B793-7D67-4227-97E5-2D05E49930B2

Q37108920-161991FE-0ACA-465C-A9C4-6F2535C1ED09

Q37108920-16DAAFF1-4071-4F77-9E1F-D06AFB2A41B4

Q37108920-2EC508DE-A25E-46CA-8FEA-617C690E548E

Q37108920-590A2EB6-B4EC-4E5C-91E2-9EE912B03820

Q37108920-602E68E5-DC42-4AF6-8D0A-2701A6F31ABB

Q37108920-729688F3-5708-4F11-91FE-3B6A5E6E9576

Q37108920-75EC469B-04B5-470A-9B26-8E883E9D7523

P304

Q37108920-EB95A14E-4DDA-46A3-BDD8-8C8BBF33EE7C

P31

Q37108920-F297B3F5-04AB-4D2D-9E51-B3FAB205C0BC

P356

Q37108920-27AD524D-75E6-41EE-990C-09A0360E29B5

P407

Q37108920-5C8BFCAC-926A-4F8B-BD7E-95846DA00867

P433

Q37108920-290C9C15-9B05-4CD6-98FF-4D570764BC8A

P478

Q37108920-DA2E3EBB-C47C-4207-B2EC-D75FE09D6C23

P50

Q37108920-58BF5AFB-7335-4417-AA3F-8E49578B1DE6

Q37108920-E91E011F-9B3B-4AB0-8174-127ACB1BE6C9

P577

Q37108920-B7862F7C-0583-4BD8-9A36-9CC4BA5754ED

P698

Q37108920-1260E2BA-18D7-47AD-B6EC-CDBC213009F9

P921

Q37108920-CD9E0583-E637-403B-AD2F-BDC9C98D6BA7

P932

Q37108920-8B731EA7-6B70-4B37-A728-56F3C29FD629

P356

P1433

Bulletin of the World Health Organization

P1476

Schizophrenia treatment in the ...... al cost-effectiveness analysis

@en

P2093

Dan Chisholm

http://www.w3.org/2001/XMLSchema#string

Jose-Luis Ayuso-Mateos

http://www.w3.org/2001/XMLSchema#string

Marcelo Villalón Calderón

http://www.w3.org/2001/XMLSchema#string

Nalaka Mendis

http://www.w3.org/2001/XMLSchema#string

Rajitha Wickremasinghe

http://www.w3.org/2001/XMLSchema#string

Sandra Saldivia

http://www.w3.org/2001/XMLSchema#string

P2860

A systematic review of the prevalence of schizophrenia.

Recovery from psychotic illness: a 15- and 25-year international follow-up study

Chlorpromazine versus placebo for schizophrenia

Econometric estimation of country-specific hospital costs

Generalized cost-effectiveness analysis for national-level priority-setting in the health sector

WHO Framework Convention on Tobacco Control: development of an evidence based global public health treaty.

Methods to assess the costs and health effects of interventions for improving health in developing countries

Evaluation of current strategies and future priorities for improving health in developing countries.

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

Cost-effectiveness of an essential mental health intervention package in Nigeria

P304

542-551

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2471/BLT.07.045377

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

86

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18670667

http://www.w3.org/2001/XMLSchema#string

P921

P932

2647485

http://www.w3.org/2001/XMLSchema#string